{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-23-000026","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.741878+00:00","generated_at":"2026-06-16T09:40:01.307004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q1 2023: Revenue $6.1B (-2%); GAAP EPS $5.28; non-GAAP EPS $3.98 (-6%)","bullets":["Total revenues $6.1B (-2% YoY); product sales +2% with 14% volume growth; ex-U.S. volume grew 22%.","GAAP EPS $5.28 (+97% YoY) on BeiGene mark-to-market gain; non-GAAP EPS $3.98 (-6%) driven by higher R&D.","GAAP operating income $1.9B (32.9% margin); non-GAAP operating income $2.8B (48.3% margin).","Free cash flow $0.7B vs $2.0B in Q1 2022, due to payment timing and higher capex for new facilities.","CEO reaffirms planned closing of Horizon Therapeutics acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-23-000026","json":"https://secwatch.observer/filing/0000318154-23-000026.json","markdown":"https://secwatch.observer/filing/0000318154-23-000026.md","text":"https://secwatch.observer/filing/0000318154-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000026/0000318154-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000026/amgn-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T09:40:01.307004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"651e562c3eeb2959c7023461c0baa3bcba88a9c9","claim":"AMGEN INC reported three months ended March 31, 2023 results: revenue $6.1 billion, EPS $5.28.","evidence_excerpt":"Key results include: • Total revenues decreased 2% to $6.1 billion in comparison to the first quarter of 2022, resulting from lower Other Revenue from our COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. Produ ct sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels and 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues were largely unchanged from Q1 2022. ◦ Volume growth of 14% included double-digit volume growth from EVENITY ® (romosozumab-aqqg), BLINCYTO ® (blinatumomab), Nplate ® (romiplostim), LUMAKRAS ® /LUMYKRASTM (sotorasib), AMJEVITA ® /AMGEVITATM (adalimumab), Repatha ® (evolocumab), KYPROLIS ® (carfilzomib) and Vectibix ® (panitumumab). ◦ Ex-U.S. volume grew 22%, including 47% volume growth in the Asia Pacific region. • GAAP earnings per sha","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000026/0000318154-23-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$6.1 billion"},{"label":"EPS","value":"$5.28"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}